Inovio Pharmaceuticals(US:INO) Globenewswire·2026-03-04 15:48Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals due to allegations of violations of federal securities laws related to misleading statements and inadequate disclosures regarding the company's manufacturing and regulatory processes for its INO-3107 treatment [4][6]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi is encouraging investors who suffered significant losses in Inovio between October 10, 2023, and December 26, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Inovio, with a deadline of April 7, 2026, for investors to seek the role of lead plaintiff [4]. - The complaint alleges that Inovio and its executives made false and misleading statements regarding the manufacturing of the CELLECTRA device and the prospects of the INO-3107 Biologics License Application (BLA) [6]. Group 2: Regulatory and Financial Impact - The FDA accepted Inovio's BLA for INO-3107 on a standard review timeline, indicating that the company did not provide sufficient information for accelerated approval [7]. - Following the FDA's announcement, Inovio's stock price dropped by $0.56 per share, or 24.45%, closing at $1.73 per share on December 29, 2025 [8]. - Inovio plans to request a meeting with the FDA to discuss potential pathways for pursuing accelerated approval despite the current setback [7].